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The purpose of this thesis was to determine whether K-opioid
and a2-noradrenergic systems interact when mediating the
ultrasphic vocalizatidns ,(yS¥) and Idcomotor activity of

preweanling rats.

In order to determine whether these

neurotransmitter systems interact, rats were treated with
various combinations of K-opioid and a?.-noradrenergic

agonist and antagonist drugs.

It was predicted that k-

opioid ahd af-ndradrenergic systems would interact to
mediate USV production, but not the locomotor activity, of

11-day-old rats.

In the first experiment, USVs and line-

crosses were measured for 20 min after rat pups were given

an injection of saline or the a2-noradrenergic agonist
clonidine (0.05, 0.1, 0.25, or 0.5 mg/kg, ip).

Clonidine

caused a dose-dependent increase in USV production and
reduced locomotor activity.

In the second experiment,

interaction of the K-opioid and the a2-noradrenergic systems

was examined by injecting rats with the K-opioid antagonist
nor-BNI (0, 5, or 10 mg/kg, ip), followed by an injection

of saline, the K-opioid agonist U50,488 (2.5 mg/kg, ip), or
clonidine (0.25 mg/kg, ip).

nor-BNI reduced USD,488-, but

111

not clonidine-> induced USV production.

nor-BNI also

decreased U50,488-induced line-crosSes.

In the third

experiment., : the interaction of K-opioid and a2-noradrenergiC:
systems was further examined by co-administering the a2

noradrenergic antagonist yohimbine (0.0, 0.5, or 1.0 mg/kg,

ip) and salirie, U50,488 (2.5 mg/kg), or clonidine (0.25
mg/kg).

interestingly, yohimbine decreased both U50,488-'

and clonidine-induced USV production.

Yohimbine also

reduced U50,488-.ind,uced line-crosses.

These findings

confirm that k-opioid and a2-noradrenergic systems interact
to mediate USV production, however the pattern of the

interaction was more complex than originally predicted.

.

More specifically, K-opioid and a2-noradrenergic systems
interact in a unidirectional manner when mediating USV

production, with the K-opioid receptors located "up-stream"
from the noradrenergic neurons.
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Introduction

Animal models of distress and anxiety

Distress and anxiety have been extensively
investigated using a variety of animal models.

For

instance, behavioral studies have shown that adult rats

often urinate, defecate, and exhibit increased exploratory
behaviors, all of which are measures of anxiety in rats
(Archer, 1973; Crawley, 1985; Russell, 1973; Walsh &

Cummins, 1976).

In addition, anxiety reduces the locomotor

activity of rats in the open arms of an elevated plus-maze
(Fellow, Chopin, File, & Briley, 1985).

There are many

physiological correlates with anxiety and distress, as

anxious rats and mice have enhanced levels of plasma
corticosterone and other stress-related hormones (Hennessy

& Levine, 1979; Misslin & Cigrang, 1986).

Therefore, it

appears that anxiety and distress can,be assessed in adult

rats using both behavioral and physiological measures.
In contrast to adult models, developmental animal

models of distress and anxiety are limited due to size of

the young rat, physiological immaturity, and inability to
perform required tasks.

Therefore, more Suitable behaviors

must be used to accurately assess distress anxiety in young
rats.

One commonly used measure of distress anxiety is

ultrasonic vocalizations (USV).

USVs are often considered

to be an emotionally-mediated behavipr that may reflect
distress in young rodents (Winslow & Insel, 1991a).

Nearly

45 years ago, Zippelius and Schleidt (as cited in Hofer &
Shair, 1978) found that young mice emit USVs when isolated
from the dam.

Since then various investigators have

examined the behavioral and neurochemical characteristics

of ultrasound production in rats and mice.
Characteristics of USVs in young and adult rats.

Since their discovery 45 years ago, USVs have been

rigorously studied in neonatal and preweanling rats.

USVs

produced by young rats range from 30-50 kHz, which is
beyond the range of human hearing (Noirot, 1968; Sewell,
1970)

Young rats begin emitting USVs shortly after birth,

with the frequency of vocalizations increasing until they
reach a peak at 10 to 13 days of age.

USVs decline soon

after this time, and are almost completely absent after 20

days of age (Hofer & Shair, 1978; Kehoe & Harris, 1989,*
Noirot, 1968).

Adult rats also emit USVs, but these calls

typically range between 20-24 kHz (Thomas, Takahashi, &
Barfield, 1983).

These vocalizations are produced as rats

engage in copulation and aggressive behaviors (Cagiano et
al., 1989; Thomas et al., 1983).

Altogether, it appears

that ultrasound production undergoes a number of
ontogenetic changes: First, the total number of USVs

produced by rats declines across ontogeny and, second,
situations resulting in the production of USVs show agedependent differences.
; Distress and cardiovascular models of USVs.

In recent

years, controversy has developed about the role of USVs in
young rodents.

Specifically, USVs were originally

interpreted to be an emotionally-mediated behavior
exhibited by young rats (Noirot, 1968); however/ Blumberg

and colleagues have challenged this view by providing
evidence that USVs are by-products of changes that occur in
the cardiovascular system (Blumberg, Sokoloff, & Kent,
1999).

The distress model.

In neonatal and preweanling rats,

USVs are emitted when the pup is separated from its
littermates and dam (Hofer & Shair, 1978; Noirot, 1972).

This separation causes the pup to produce ultrasounds that
elicit maternal retrieval, caregiving, and aid in

thermoregulation (Bell, 1979; Hofer & Shair, 1978; Sales &
Smith, 1978; Smotherman et al., 1974).

Thus, separation

from the dam and littermates is presumed to be distressing

to the young pup and the resulting vocalizations are

interpreted to be a product of their emotional state.

Frequency of isolation-induced USVs can be altered by
various factors, such as cold temperature, presentation of
the dam, and presentation of an unfamiliar adult male.

For

. instance, rat pups emit USVs when isolated, in a cold

environment (Allin & Banks, 1971; Blumberg et al., 1998).
USVs emitted during cold exposure provoke maternal

retrieval for assistance in thermoregulation (Allin &
Banks, 1971).

Hence, USVs may be emitted to resolve

physiological discomfort experienced in a cold environment.
Besides being temperature dependent, USVs can be

altered in various social situations.

For example, an

isolated pup will decrease its vocalizations when an

anesthetized dam is presented to the pup (Garden & Hofer,

1992).

The decrease in vocalizations is independent of the

dam's ability to assist in the thermoregulation of the pup,
because pups will decrease their vocalizations even when

the dam's body temperature is significantly below normal
levels (Garden & Hofer, 1992; Hofer, Brunelli, & Shair,

1993),

Upon removal of the dam, the rat pup emits

vocalizations at an even, greater rate than it did initially
(known as potentiation; Hofer, Masmela, Brunelli, & Shair,

1998).

However, suppression of USVs and motor; movement

(i.e., freezing) is observed when an unfamiliar adult male

is placed in the same environment with the rat pup
(Takahashi, 1992).

Interestingly, the isolated rat pup

continues to remain quiet after the unfamiliar male is
removed (known as inhibition; Shair, Masmeia, & Hofer,

1999).

The potentiation and inhibition of USVs appears to

be emotionally-mediated, because young rats exposed to
extreme cold temperatures also increase their USVs or

remain quiet upon removal of the dam (or an adult male

(Shair, , Masmeia, Brunelli, &/Hofer, 1997).

In summary, it

is evident that isolation-induced USV production can be
modulated by various situational factors.
Psychopharmacological manipulations are capable of

modulating separation-induced USVs.

Drugs that are known

to be rewarding (e.g., morphine and cocaine) or anxiety
reducing (e.g., diazepam) decrease USVs (Garden & Hofer,
1990; Insel, Hill, & Mayor, 1986; Kehoe & Blass, 1986;
Kehoe & Boylan, 1992; Nazarian, Rodarte-Freeman, &

McDougall, 1999; Winslow & Insel, 1991b).

However, drugs

that enhance USVs may do so by having either.
anxiogenic/aversive properties (Hansen, 1993; Mucha & Herz,
1985) or by directly activating neural pathways that

mediate USV production (Goodwin & Barr, 1997; Jiirgens,

1994).

For example, the K-opioid agonist U50,488 and the

as-noradrenergic agonist cionidine increase the USVs of:

^

young rats (Barr, Wang, & Garden, 1994; Blumberg, SokOloff,

Kirby, & Kent, 2000; Hard, Engel, & Lindh, 1988; kehoe^^^&

Boylan-,,j 1994; Kehoe & Harris, 1989; Nazarian et al.

l-gsiS') i'.)

Cionidine- and U50,488-induced vocalizations are not

suppressed when the rat pup is placed back in the home cage
(Garden, Davachi, & Hofer, 1994; Hansen, 1993), suggesting

that these drugs may enhance USVs by stimulating pathways
mediating USV production (i.e., these actions may be
independent of the drug's aversive or anxiogenic
properties).
Various brain regions are involved in the production
of USVs.

Receptor localization studies have shown the

presence of both K-opioid and noradrenergic receptors in the
striatum and amygdala, areas known to be important for

affective behaviors.

Furthermore, USV production is

correlated with Fos-like immunoreactivity in the amygdala,
prefrontal cortex, and periaqueductal gray (PAG) of adult
rats (Fos is a quick-developing protein that can be used as
a regional marker of neuronal activation) (Duncan, Knapp, &

Breese, 1996).

Additional evidence suggests that the PAG

may be of special importance, as microinjecting U50,488
into the PAG enhances USV production in young rats (Goodwin
& Barr, 1997).

Finally, the amygdala and PAG are

extensively interconnected, suggesting that these two brain

regions may jointly mediate some behaviors, perhaps
including USVs (Rizvi, Ennis, Behbehani, & Shipley, 1991).
Taken together, these results suggest-that.USO,488 and

clonidine may affect USV production by stirriulating K-opioid

and noradrenergic receptors in the amygdala and/or PAG.
The cardiovascular model.

In the past decade,

traditional views about USVs have been challenged by

studies questioning the validity of the distress model.
More specifically, Blumberg and colleagues argue that USVs
are by-products of a cardiovascular process known as the

abdominal compression reaction (ACR; Blumberg et al.,
1999).

The ACR is a mechanism that helps move venous blood

back to the heart by the contraction of abdominal muscles

during expiration (Youmans, Tjide, & Tong, 1974).

The

mechanisms involved in ACR-induced USVs are as follows.

An

isolated rat pup has difficulty thermoregulating, thus its
body temperature decreases when isolated.

This decrease

causes heart muscles to cool down and/ consequently, both
heart rate and blood pressure are reduced (Blumberg,
Sokoloff, & Kirby, 1997).

The decrease in heart rate

causes a reduction of venous flow.

Therefore, the ACR

assists in propelling the venous blood back to the heart

(Blumberg et al., 1999),

Ultrasonic, vocalizations are,

therefore, a by-product of air released by the larynx
during expiration.

The young rat has a physiological mechanism that can
combat the decrease in body temperature.

Rats as well as

Other mammals have brown adipose tissue (BAT) surrounding

critical organs in the body.

The role of BAT is to assist

in thermoregulation when body temperature decreases (Smith,
1964).

Thermoregulation occurs by increasing the

metabolism of BAT, resulting in an increase in temperature,
which then warms up the critical organs that it surrounds

(e.g., the heart; Smith, 1964).

The heating of BAT

prevents heart muscles from cooling down,, thus preventing a
decrease in heart rate (Blumberg et al., 1997).

The

ability of BAT to assist in thermoregulation is limited,

because extreme cold temperatures can overwhelm the
capacity of BAT to maintain the necessary temperature to
prevent the heart from slowing down (Blumberg et al., 1997;

Blumberg & Stolba, 1996).

During such situations, the";'

animai involuntarily engages in ACRs to maintain blood
pressure and prevent further decreases of heart rate

(Youmahs et al;.,,l. 1974:) .-/.Due to .the inability, of BAT to
.thermoregulate, USVs are emitted as by-products of the ACR.
As noted earlier, psychopharmacological manipulations
can alter USV levels, therefore it is possible that these

cardiovascular mechanisms can be activated using various
drugs.

Interestingly, drugs that enhance USVs often affect

the cardiovascular system.

For instance, both the K-opioid

agonist U50,488 and the as-noradrenergic agonist clonidine
decrease body temperature, heart rate, and blood pressure
of rats (Gautret & Schmitt, 1985; Ledda, Mantelli, & Corti,
1985; Szabo, Bock, Nordheim, & Niederhoffer, 1999).

Interestingly, K-opioid and as-noradrenergic systems
interact when modulating rabbit and guinea pig heart
functioning.

For example, stimulation of K-opioid

receptors, located on peripheral noradrenergic nerve
terminals, inhibits the release of norepinephrine at the

/

heart (Fuder, Buder, Riers, & Rothacher, 1986; Ledda et

al., 1985; Starke, Schoffel, & Illes, 1985).

Similarly,

:stimulation of presynaptic'as-adrenoceptors in the, periphery.

also inhibits the release of norepinephrine at the heart
: (Korner et al., 1983; Van Zwieten, 1986).

Inhibiting

norepinephrine release by K-opioid or a2-adrenoGeptor

^

'

stimulation decreases heart rate (bradycardia) (Fuder et
al., 1986; Van Zwieten, 1986).

Centrally mediated

cardiovascular responses can decrease heart rate and blood
pressure asiwell.

feceptprs

For instance, activation of K-opioid

hippocampal and hypothalamic regions prbduces,

bradycardia and hypotension (Wang & Ingenito, 1994).

Based

on the evidence presented, it is possible that U50,488 and

Clonidine increase USVs through either peripherally- or
centrally-mediated cardiovascular mechanisms.
■P: Summary and proposal.

At present, USV production can

be explained using either the distress model or the
cardiovascular model.

The distress model states that USVs

are an emotionally-mediated behavior produced by rat pups
when separated from their mother and littermates.

These

vocalizations are therefore emitted, either intentionally

or unintentionally, to attract the mother for nurturance,
protection, and assistance in thermoregulation.

The

cardiovascular model, however, argues that USVs are simply
by-products of ACRs.

Thus, ultrasound production is

10

.

considered to be a residual effect, as the young rat

invdlnhtarily engages in ACRs to drive venous blood back to
Athe: heart> ,

. .

■ Drug-induced changes in trsvs can be explained using
both; the distress and cardiovascular models..

That is.,..

U50,488 and clonidine may increase USVs by: a) directly
affecting neuronal mechanisms mediating distress, or b)
altering heart rate, blood pressure and body temperature.

Therefore, my long-term goal is to determine the underlying
mechanisms by which K-opioid agonists and noradrenergic
agonists produce vocalizations.

As an initial step, I want

to determine whether the K-opioid and as-noradrenergic
systems interact when mediating USV production.
K-Opioid and g-noradrenergic systems

K-Opioid and a-noradrenergic receptors are intimately
involved in USV production in young rats.

For instance,

both the K-opioid agonist U50,488 and the a2-noradrenergic

agonist clonidine enhance USVs of neonatal and preweanling
rats (Garden et al., 1994; H^rd et al., 1988; Kehoe Sc

Boylan, 1994; Kehoe & Harris, 1989; Nazarian et al., 1999).
It is currently not known whether stimulation of the k-

opioid system is necessary for a-noradrenergic-induced

USVs.

As noted earlier, it is possible that these two

systems interact either centrally or peripherally to

enhance USVs.

Stimulation of a-noradrenergic or K-opioid

receptors located on noradrenergic nerve terminals in the

heart inhibits the release of norepinephrine, ' The reduced
levels of norepinephrihe cause bradyeardia, which may then
enhance- USVs;

However, it is also possible that K-opioid

and noradrenergic systems interact in the - amygdala, -/
striatum, or PAG to increase USVs.

To date, the

interaction of K-opioid and a-noradrenergic system on the
USVs of young rats has not been examined.

Consequently,

studying how these two systems interact is crucial for
better understanding the underlying mechanisms responsible
for USV production.

K-Opioid receptors.

Since the discovery of K-opioid

receptors in the early 1980's, three K-opioid receptor
subtypes have been characterized: Ki, K2, and K3 (Cheng,
Rogues, Gacel, Huang, & Pasternak, 1992; Fowler & Eraser,

1994; Leslie & Laughlin, 1994; Unterwald, Knapp, & Zukin,
1991).

The K-i-opioid receptor subtype has a high affinity

for the endogenous peptide dynorphin A and exogenous
arylacetamide drugs such as U50,488 and U69,593 (Devlin &

12

Shoemaker, 1990; Unterwald et al., 1991).

The K2-opioid

receptor has a higher affinity for dynorphin A and

exogenous drugs such as bremazocine (Underwald et al.,
1991).

Because of the limited understanding of Ks-opioid

receptors, the only.drug that has specific affinity for
this .recaptor subtype is naloxone benzoylhydrazone (Cheng
et al., ■ 1992). ,

Ki-Opioid.receptors are found in various brain regions,
including the striatum, ■nucleus accumbens, olfactory
tubercle, amygdala, central medial nucleus of the thalaraus,

vehtral tagmental area, periagueductal gray, and substantia
nigra pars reticulata (Mansour, Burke, Pavlic, Akil, &
Watson, 1996; Unterwald et al., 1991) .

In general, K2

opioid receptors are found in greater densities in the
brain than Ki-opioid receptors.

K2-0pioid receptors have

been localized in the striatum, nucleus accumbens,

olfactory tubercle, claustrum, endopiriform nucleus,
various thalamic regions, and inferior colliculus.
(unterwald et al. , 1991) .

The limited number of studies

examining Ks-opioid receptors suggest that they can be found
in the thalamus, hypothalamic areas, hippocampus, striatum,

and midbrain (Chengvet al. , 1992) .
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Localization of K3

opioid receptors are based on homogenate receptor binding

assays (Cheng et al., 1992), while Ki-opioid and K2-opioid
receptor localization is based on receptor autoradiography
assays (Devlin & Shoemaker, 1990; Unterwald et al., 1991).

Receptor autoradiography is more appropriate for studying

regional differences in receptor topography than homogenate
receptor binding assays (Feldman, Meyer, & Quenzer, 1997,
pp. 31).

Behavioral effects of K-opioid receptor stimulation in

the adult rat.

Stimulatibn of,. K-opioid receptors produces

antinociception in a variety of analgesia paradigms.

For

instance, the K-opioid receptor agonist U50,488 increases
radiant heat tail-flick latencies and hind paw withdrawal
latencies in the formalin test, and decreases abdominal

licking to visceral pain (Craft, Henley, Haaseth, Hruby, &
Porreca, 1995; Idanpaan-Heikkila, Kalso, & Seppala, 1994;
McLaughlin, Tao, & Abood, 1995; Millan, Czlonkowski,

Lipkowski, & Herz, 1989). Moreover, the K-opioid antagonist
nor-BNI attenuates U50,488-induced antinociception (Craft
et al., 1995; McLaughlin et al., 1995; Millan et al.,
1989).

Therefore, these results demonstrate that U50,488

14

induced antinociception is mediated by activation of kopioid receptors.

K-Opioid receptor agonists produce a dose-dependent
decrease in the locomotor activity of adult rats and mice

(Jackson & Cooper, 1988; Leyton & Stewart, 1992; McLaughlin
et al., 1995; Ukai & Kameyama, 1985; VonVoigtlander, Lahti,

Sc Ludens, 1983). Thus, high doses (10 mg/kg) of U50,488
attenuate the locomotor activity of adult rats, while lower

doses (1 mg/kg) of U50,488 have no effect (Jackson &
Cooper, 1988; Ukai &:Kameyama, 1985).

U50,488's

hypolocomotive effects are reversed by the K-opioid receptor
antagonist nor-BNI (Jones & Holtzman, 1992).

In summary,

it is evident that K-opioid agonists reduce the locomotor

activity of adult rodents via stimulation of K-opioid
receptors.

In addition to producing analgesia and affecting
locomotor activity/ activation of K-opioid receptors appears

to have some aversive properties.

For example, stimulation

of K-opioid receptors using U50,488 or dynorphin derivatives
(e.g., E-2078) results in conditioned place and taste
aversions (Bals-Kubik, Herz, & Shippenberg, 1989; Mucha &

Herz, 1985; Shippenberg & Herz, 1986; but see Crawford,
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McDougall, Bolanos, Hall, & Berger, 1995).

Moreover, k-

opioid receptor stimulation has been shown to be aversive
when assessed in a self-administration paradigm (Pi Chiara
& Imperato, 1988b; Holtzman & Steinfels, 1994).

Although

speculative, U50,488-induced aversions and hypolocomotion
may be due to K-opioid-mediated reductions in extracellular
dopamine in the nucleus accumbens and striatum (brain
regions known to mediate both reward and locomotor
activity) (Di Chiara & Imperato, 1988a; Maisonneuve, Archer

& Glick, 1994; Spanagel, Almeida, Bartl, & Shippenberg,
;■

1994).

.

Behavioral effects of K-opioid receptor stimulation in
the preweanlinq rat

Depending on the behavior,

stimulation of K-opioid receptors may produce adult-typical
or adult-atypical effects in preweanling rats.

Unlike

adults, stimulation of K-opioid receptors increases the
locomotor activity of preweanling;rats.

For example, both

systemic and intranigral injections of K-opioid receptor
agonists enhance the locomotor activity of 3 -, 10-, and 17
day-old rats (Collins, Zavala, Nazarian, & McDougall, 2000;
Duke, Meier, Bolanos, Crawford, & McDougall, 1997; Jackson

Sc Kitchen, 1989; Kehoe & Boylan, 1994; McDougall, Rodarte

■ ■ ■

■

■

'O'- -i''
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Freeman, & Nazarian, 1999; McLaughlin et al., 1995).

This

increase in locomotion is blocked by systemic, as well as

intranigral, injections of nor-BNI (Collins et al., 2000;
McLaughlin et al., 1995), thus indicating that K-opioid
agonists produce their locomotor activating effects by

stimulating K-opioid receptors in the substantia nigra pars
reticulata (Collins et al., 2000).

Similar to adults, preweanling rats given K-opioid
receptor agonists exhibit analgesic responses on tailflick, hot-plate, formalin, and mechanical pain tests
(Barr, Miya, & Paredes, 1992; Barr, Paredes, Erickson, &
Zukin, 1986; Giordano & Barr, 1988; Kehoe & Boylan, 1994;

McLaughlin et al., 1995; Nazarian et al., 1999).

K-Opioid

induced analgesia in the formalin test is blocked by the

selective K-opioid receptor antagonist nor-BNI (McLaughlin
et al., 1995).

Analgesia produced by stimulation of k-

opioid receptors is mediated through both spinal and

superspinal sites (Barr et al., 1992; Goodwin, Wiedenmayer,
Sc Barr, 1998).

Of course, U50,488 greatly enhances USVs in neonatal
and preweanling rats (Barr et al.,. 1994; Garden, et al.,
1994; Kehoe & Boylan, 1994; Nazarian et al., 1999).
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U50,488-induced USVs may result from aversive properties of
the drug, or K-opioid receptors may directly mediate
distress-induced vocalizations.

These results indicate

that preweanling rats have adult-typical analgesic and
aversive reactions to K-opioid agonists, while the

mechanisms responsible for K-opioid-mediated USVs and
distress are not well understood.

g-Noradrenergic receptors (adrenoceptors).

Knowing

the neuroanatomical location and affinity of receptors is

important when studying the functional role of receptor

subtypes in the brain.

Recent studies have categorized a

adrenoceptors into two subtypes: ai and aa.

ai-

Adrenoceptors are found primarily in the cerebral cortex,
striatum, thalamus, hypothalamus, hippocampus, pons,

medulla, cerebellum, and spinal cord (Wilson & Minneman,

1989).

Moreover, tti-adrenoceptors are characterized by

having high affinities for agonist drugs such as
cirazoline, methoxamine, and phenylephrine.

These

receptors also have high affinities for antagonists such as
prazosin, WB-4101, and phenoxybenzamine (Ruffolo, Nichols,
Stadel, & Hieble, 1991).

,
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aa-Adrenoceptors are found in somewhat different
regions than ai-adrenoceptors.

For example, a2

adrenoceptors are found in the locus coeruleus,
hypothalamus, basolateral and central amygdala, thalamus,
substantia nigra pars reticulata, dentate gyrus, striatum,

CAl pyramidal cells, and hippocampus (Wamsley, Alburges,
Hunt, & Bylund, 1992).

Noradrenergic agonists such as

clonidine, a-methyl-norepinephrine, and UK-14,304 stimulate
a2-adrenoceptors, while yohimbine, idazoxan, and rauwolscine

antagonize a2-adrenoceptofs (Ruffolo et al., 1991).
Behavioral effects of a-adrenoceptor stimulation in
1

the adult and preweanling rat.

Stimulation of a

adrenoceptors by clonidine (an 0.2 preferring agonist)

results in the suppression of various behaviors in adult
rats.

For instance, clonidine decreases the locomotor

activity, wall climbing, and nociception of adult rats
(Delini-Stula, Baumann, & Buch, 1979; Drew, Gower, &

Marriott, 1977; Fielding, Spaulding, & Lai, 1981; Fielding
et al., 1978; Reinstein & Isaacson, 1977; Smythe & Pappas,
1989).

Moreover, stimulation of a2-adrenoceptors by

clonidine causes sedation, catalepsy, and suppresses
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avoidance acquisition (Kostowskiet al. > 1981; Laverty &
Taylor, 1969; Reinstein & Isaacson, 1977).

The depressive

effects of clonidine are due to the stimulation of central

a2-noradrenergic autoreceptors which attenuate the release
of norepinephrine from nerve terminals (Delini-Stula et
al., 1979; Drew, Grower, & Marriott, 1977).

Clonidine does

have some rewarding properties, because it produces
conditioned place preferences in adult rats (Asin &
Wirtshafter, 1985).

In contrast to adults, young rats show different

behavioral reactions to adrenoceptor agonists.

More

specifically, stimulation of a2-adrenoceptors enhances USVs,

general motoric movement, wall climbing, antinociception,
and decreases olfactory place preference of home cage odor
(Blumberg et al., 1999; Hansen, 1993; Hard et al., 1988;
Kehoe & Harris, 1989; Smythe & Pappas, 1989).

Clonidine

induced USVs and locomotor activity are inhibited by
yohimbine and idazoxan (a2-receptof antagonists) in a dosedependent manner (Hard et al., 1988; Kehoe & Harris, 1989;
Nomura & Segawa, 1979).

When considered together, it is

evident that stimulation of a-adrenoceptors produces
different behavioral effects in young pups than adult rats.
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thus indicating that the noradrenergic system undergoes

ontogenetic changes across the preweanling period.
Cardiovascular system

Effects of K-Opioid receptor stimulation on the

cardiovascular system.

Numerous studies have shown the

presence of K-opioid receptors in rat heart (Tai, Jin,. Chan,
& Wong, 1991; Zhang, Wang, Xia, & Wong, 1997; Zimlichman et
al., 1996).

Peripheral administration of endogenous and

exogenous K-opioid ligands (e.g., dynorphin (1-13) or
1750,488) decreases heart rate (bradycardia) and blood

pressure of adult rats (Gautret & Schmitt, 1985; Ledda et
al., 1985; Pugsley, Penz, Walker, Wong, 1992a,- 1992b;

Pugsley, Saint, Penz, & Walker, 1993).

Interestingly, k-

opioid receptor agonists produce bradycardia through two

distinctly different mechanisms of action.

At lower doses,

1750,488 produces bradycardia by stimulating K-opioid
receptors in the heart; while at higher doses 1750,488

produces bradycardia by blocking Na"^ and K'*' currents in
heart muscles (Gautret & Schmitt, 1985; Pugsley et al.,

1992a; Pugsley et al., 1993; Pugsley, Saint, & Walker,
1994; Wong, Lee, & Tai, 1990).

When administered at lower

doses, 7750,488-induced bradycardia is blocked by the k
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opioid receptor antagonist MR 2266, or the non-selective

opioid antagonist naloxone (Wong et al., 1990).

At higher

doses, U50,488-induced bradycardia is not affected by MR

2266 or naloxone (Pugsley et al., 1992a).

Therefore, it

appears that K-opioid-induced bradycardia is mediated by two
different mechanisms in rat heart.

In addition to these peripherally mediated effects,
heart rate and blood pressure can be affected by central

administration of drugs.

There are various brain regions

that, when stimulated, can alter heart rate and blood

pressure.

For example, U50,488 infused into the

hippocampus or hypothalamus produces bradycardia and
hypotension; similar to the effects of peripherally
administered K-opioid agonists (Feuerstein & Faden, 1982;
Wang & Ingenito, 1994).

Altogether, at least two possible mechanisms of action
can account for K-opioid mediated bradycardia and
hypotension.

Peripherally, K-opioid receptor stimulation at

the heart can produce bradycardia and hypotension.

While,

central activation of K-opioid receptors in the hippocampus
or hypothalamus can also decrease heart rate and blood
pressure.
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Effect of g-noradrenerqic receptor stimulation on the

cardiovascular system; .. the a-n

is

intimately involved in the normal fuhctioning of the heart.
Consequently, modulation of the a-noradrenergic system

using agonist and antagdnist'drugs can. signifiGantly alter
heart /rate, and blood pressure of the organism.

For .. . ■

instance, /stimulation of. cardiacV;ai;-^adrehoceptors by ..

endogenous or exogenous ligands increases heart rate and
blood pressure (Van Zwieiteh, Timmermans, & Van Brummelen,
1984;/Van Zwieten, Van Meel, &' Tot

1982). . In rat

heart, ai-adren6ceptors appear to be exclusively located on

postsynaptic terminals (Wagner & Brodde, 1978).
Unlike ai-adrenoceptors, a2-adrenoceptors are located
on presynaptic terminals in rat heart (Langer, 1981;
Starke, 1977; Westfall, 1977).

Stimulation of tta- /

adrenoceptors by norepinephrine or .clonidine inhibits

norepinephrine release from presynaptic terminals (Korner
et al., 1983; Van Zwieten, 1986).

Therefore, stimulation

of a2-adrenoceptors reduces blood pressure and heart rate in

rats by reducing norepinephrine levels at the heart (Korner
et al., 1983; Szabo et al., 1999).
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In summary, stimulation

of postsynaptic ai-adrenoceptors increases heart rate and
blood pressure, while stimulation of presynaptic a2
adrenoceptors decreases heart rate and blood pressure.
Overview

:

mentibnfed/:-tJSV^;

has been

explhiried by two distinctly different models
model and the cardiovascular model.

the distress

Tlie distress model

suggests that USVs are an emotiOhaliy-mediated reaction
exhibited by young pups. ^This model; is supported by: ^
findings showing that young rats emit USVs when separated /
from their dam and littermates.

Pharmacological findings

indicate that various drugs alter USV production.

For

instance, morphine, cocaine, and diazepam reduce
vocalizations, while U50,488 and clonidine enhance
vocalizations.'

In opposition to the distress model, the

cardiovascular model suggests that the cardiovascular

system may be ultimately responsible for both U50,488- and
clonidine-induced vocalizations.

That is, alterations in

the cardiovascular system due to isolation or drugs may

result in the production of USVs.

Pharmacological evidence

indicates that both U50,488 and clonidine produce
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bradycardia, hypotension, and hypothermia.

These

cardiovascular effects are important factors that can

activate ACRs and, thus, produce USVs.

Therefore, it is

possible that isolation-ihduced and pharmacologically- "
induced USVs are due to cardiovascular mechanisms instead

of emotionally-induced reactions such as distress.

Altogether, it appears that activating K-opioid and
noradrenergic systems enhances USV production of

preweanling rats.

This increase may be due to either

emotional- or cardiovascular-mediated actions.

Because k-

opioid and noradrenergic agonist drugs increase USVs, it
appears that both the K-opioid and noradrenergic
neurotransmitter systems mediate USV production.

It is

uncertain, however, whether these two neurotransmitter

systems interact to mediate USVs.
Thesis

;

The purpose of. this .theslS: was to determine whether
the K-opioid and a2-noradrenergic systems interact to

mediate USV production of preweanling rats.

The

interaction of these systems was assessed by using the kopioid agonist U50,488, the K-opioid antagonist nor-BNI, the
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a2-noradrehe]rgic agonist: clonidine, and the a2-noradrenergic
antagonist yohimbine. .
Both USVs and line-crosseg (a reliable measure of

■ Ipcdmotor activity), were assessed in each experiment.

In

the first experiment, various doses of clonidine were
administered in order to determine a dose of clonidine that

would reliably prqduceUSVs. and line-crosses in young rats.
In the second experiment, the interaction of K-opioid and

d2-nbradrenergic systems was assessed by administering norBNI in Combination with U50,488 or. clonidine.

In the third

experiment, the interaction of K-opioid and a2-noradrenergic
systems was further assessed by administering yohimbine in
combination with clonidine or U50,488.

It was originally hypothesized that the pattern of
drug effects would differ depending on the dependent
measure (i.e., USVs, locomotor activity, and rectal

temperatures).

When assessing USV production, it was

predicted that: 1) clonidine and would produce a
progressive dose-dependent increase in USVs; 2) nor-BNI
would attenuate U50,488- and clonidine-induced USVs, and 3)

yohimbine would attenuate clonidine- and U50,488-induced
USVs.

This pattern.of results would indicate that K-opioid
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and a2-noradrenergic systems synergistically interact when
mediating USV production.

The bases for these predictions

were three-fold: first, stimulation of both K-opioid and a2

noradrenergic receptors enhances USV emissions; second, kopioid and a2-noradrenergic systems are known to have
extensive interactions in the periphery; and, third, USVs

are suspected to 'be peripherally mediated.

Because of the

extensive peripheral interactions between K-opioid and a2
noradrenergic systems, it was predicted that these two
neurotransmitter systems would interact to mediate USV
production.

A different pattern of drug-induced effects was

hypothesized for locomotor activity.

It was predicted

that: 1) clonidine would produce a progressive dosedependent increase in line-crosses; 2) nor-BNI would
attenuate U50,488-, but not clonidine-, induced line-

crosses; and 3) yohimbine would attenuate clonidine-, but
not U50,488-, induced line-crosses.

The bases for these,

predictions were two-fold: first, it is doubtful whether kopioid and a2-noradrenergic systems have extensive
interconnections in brain regions known to mediate
locomotor activity; and, second, K-opioid and a2
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noradrenergic receptor agonists are suspected of

stimulating locomotor activity via central mechanisms
(Anden et al., 1970; Collins et al., 2000; Zebrowska-

Lupina, Prezegalihski, Sloniec, & Kleinrok, 1977).

Because

of the lack of known central interconnections, it is

doubtful whether the K-opioid and a2-noradrenegic systems
interact to mediate locomotor activity.

Hypotheses about drug-induced changes in rectal

temperatures were based on previous findings.

It was

predicted that clonidine, but not U50,488, would reduce
rectal temperatures of 11-day-old rats (Blumberg, Kreber,
Sokoloff, Sc Kent, 2000; Nazarian et al., 1999).

It was

also predicted that yohimbine would attenuate clonidine
induced reductions in rectal temperatures.

Future Directions

,

This research project was the first step in
determining whether: 1) the K-opioid and a-noradrenergic

systems interact when mediating USV production, 2) the kopioid and a-noradrenergic receptors mediating USVs are
located centrally or peripherally, and 3) USVs are the
result of distress or ACRs.

In this study I directly

answered the first question, that is, whether the K-opioid
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and a2-noradrenergic systems interact when mediating USV

production.

In subsequent projects I hope to build on

these results and provide answers for all three questions
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GENERAL. METHODS

Subjects

Subjects were 115 rats of Sprague-Dawley descent
(Harlan, Indianapolis, IN).

on postnatal day (PND) 3.

Litters were culled to 10 pups

An approximately equal number of

male and female rat pups were used in each experiment.
rats were tested on PND 11.

All

Animals were housed with their

dam and littermates prior to behavioral assessment.

Rats

were randomly assigned to groups with no more then one rat
from each litter being placed in a particular group.

To

maintain litter size, previously tested animals were

anesthetized with pentobarbital and placed back in the home
cage (Garden, Bartot, & Hofer, 1993).

The colony room was

maintained at 22-24°C on a 12-hour light/dark cycle (lights
on at 6 a.m.).

Apparatus

Ultrasonic vocalizations and locomotor activity were

assessed in a Plexiglas chamber (19 x 19 x 19.5 cm) housed
inside a heated incubator (34°C).

Rectal temperatures were

taken using a RET-3 rectal probe connected to a BAT-12

thermometer (Physitemp, Clifton, NJ).

USVs were transduced

using a Mini-3 ultrasonic detector (Ultrasound Advice,
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London, England).

An experimenter blind to treatment

conditions counted vocalizations.
Drugs

(±)-trans-U-50,488 methanesulfonate, nor

binaltorphimine dihydrochloride (nor-BNI), clonidine

hydrochloride, and yohimbine hydrochloride (Sigma, St.
Louis, MO) were mixed in saline vehicle.at a volume of 5

ml/kg.

All injections were given intraperitoneally (ip).

Statistical/Analysis

Analyses of variance (ANOVAs) were used to analyze
USVs, line-crosses, and rectal., temperatures.

For all

analyses, litter effects were controlled using withinlitter statistical procedures (i.e., a within analysis with
one value/condition/iitter; Zorilla, 1997).

in order to

assess sex-ihduced behavioral effects, USVs, line-crosses,

and body temperature data were reanalyzed with sex being
included as a factor in the statistical analyses.

None of

these analyses resulted in statistically reliable effects,

so analyses including sex as a factor were not presented in
the text,.

Post hoc analysis of simple interactions and

main effects, were performed using Tukey HSD tests (p <
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0.05).

In these circumstances, Tukey tests were used to

compare drug groups to saline controls.
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EXPERIMENT ,1

The first experiment was conducted to determine a dose
of clonidine that reliably stimulates USVs in 11-day-old
rats.

It was predicted that clonidine would produce a

dose-dependent increase in USVs.
Method

Eight litters (N =40) of ll-day-old rats were

injected with clonidine (0.05, 0.1, 0.25, or 0.5 mg/kg, ip)
or saline and returned to the home cage for 15 min.

Rats

were then individually transported to the testing room and

placed in the testing chamber.
were assessed for 20 min.

USVs and locomotor activity

Rectal temperatures were taken

immediately following testing.

In Experiment 1, separate one-way (agonist drug)
ANOVAs were used to analyze USVs, line-crosses, and rectal
temperatures.

When appropriate, Tukey tests were used to

assess differences between drug groups and saline controls.
Results

Ultrasonic Vocalizations.

USVs data were analyzed

using a one-way within-subjects ANOVA (see Appendix-A).
USVs of rats given clonidine are shown in Figure 1.

Clonidine produced a dose-dependent increase in the USV
production of 11-day-old rats [agonist drug main effect,
I
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F(4, ;,2;8) ,, = 14.76, ;£ < 0.001]vi;' Specifically,v.the twov . - ;
highest doses of clonidine (0.25 and 0.5 mg/kg) produced

;

more USVs than saline [Tukey tests, p < 0.05].
Line-crosses.

Line-cross data were analyzed using a

one-way within-subjects ANOVA (see Appendix B).

Line-

crosses of young rats given clonidine are shown in Figure
2. , When compared to the saline group, all doses of
.clonidine caused a significant reduction in line-crosses

[agonist drug main effect, F(4, 28) = 4.93, p < 0.01, and
Tukey tests, p < 0.05].
Rectal Temperatures.

Rectal temperature data were

analyzed using a one-way within-subjects ANOVA (see
Appendix C).

Rectal temperatures of rats given clonidine

are shown in Figure 3.

Rats treated with higher doses of

clonidine (0.1, 0.25, or 0.5 mg/kg) had significantly lower
rectal temperatures than saline-treated rat pups [agonist
drug main effect, F(4, 28) = 12.24, p < .001,. and Tukey ,( ;
tests,
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Figure 1.

Mean ultrasonic vocalizations (+SEM) of 11-day

old,rats (n = 8) administered saline of clonidine (0.05,
0.1, 0.25, or 0.5 mg/kg) 15 min prior to behavioral

testing. ^Significantly different from saline-treated rats.
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Figure 2.

Mean line-crosses (dSEM) of 11-day-old rats (n

8) administered saline or clonidine (0.05, 0.1, 0.25, or

0.5 mg/kg) 15 min prior to behavioral testing.

^Sgnificantly different from saline-treated rats.
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Figure .3. . Mean rectal temperatures (±SEM) of ll-day-old
rats (n = 8) administered saline or clonidine (0.05, 0.1,

0.25, or 0.5 mg/kg) 15 min prior to behavioral testing.
Rectal temperatures were measured immediately following the

20 min behavioral testing session,
from saline-treated rats.
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^Significantly different

EXPERIMENT 2

In the second experiment I assessed the potential
interaction between the K-opioid and a2-noradrenergic

systems.

To do so, the K-opioid antagonist nor-BNI was

injected prior to treatment with the K-opioid agonist
U50,488 or the a-noradrenergic agonist clonidine.

It was

predicted that K-opioid receptor blockade would attenuate
both K-opioid~mediated and a-noradrenergic-mediated USV
production.
Method

Eight litters (N = 72) of ll-day-old rats were

injected with nor-BNI (0, 5, or 10 mg/kg, ip) and placed in
their home cage for 15 min.

Rat pups were then injected

with saline, USD,488 (2.5 mg/kg, ip) or clonidine (0.25

mg/kg, ip).

After an additional 15 min, USVs and locomotor

activity were measured in the testing chamber for 20 min
(divided into four 5-min time blocks).

Time blocks were

used to assess whether drug-induced effects varied as a
function of time.

Rectal temperatures were taken

immediately after testing.

Rat pups were then placed in a

room separate from their dam and littermates.
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In Experiment 2, a 3 x 3 x 4 (antagonist drug x agonist
drug X time) within-subjects repeated measures ANGVA was
used to analyze USVs.

Line-crosses and rectal temperatures

were analyzed using 3x3 (antagonist drug x agonist drug)
within-subjects ANOVAs.
Results

Ultrasonic Vocalizations.

USV data were analyzed

using a 3 x 3 x 4 within-subjects repeated measures ANOVA
(see Appendix D).

USVs of rats given nor-BNI and U50,488

or clonidine are shown in Figure 4.

Overall, rats given

U50,488 or clonidine emitted more USVs than saline-treated
rats across all time blocks (all three graphs) [agonist

drug X time interaction, F(6, 42) = 6.20, p < 0.001, and
Tukey tests, p < 0.05],

nor-BNI alone had no effect on USV

production (upper graph); however, both doses of nor-BNI (5
and 10 mg/kg) attenuated the U50,488-induced USV production
of 11-day-old rats (middle graph) [antagonist drug x agonist
drug interaction, F(4, 28) = 20.87, p < 0.001, and Tukey
tests, p < 0.05].

nor-BNI did not decrease clonidine

induced USV production (bottom graph).
Line-crosses.

Line-cross data were analyzed using a 3

X 3 within-subjects ANOVA (see Appendix E).
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Line-crosses of

rats given nor-BNI and U50,488 or clonidine are shown in

Figure 5.

U50,488-treated rats had more line-crosses than

their saline controls, while clonidine had no effect

[agonist drug main effect, F(2, 14) = 68.44, p < 0.001, and

Tukey tests, p < 0.05].

nor-BNI (5 or 10 mg/kg) attenuated

U50,488-induced line-crosses in a dose-dependent manner,
whereas nor-BNI did hot affect line-crosses of saline- or

clonidine-treated rats [antagonist drug x agonist drug
interaction, F(4, 28) =11.84, p <0.001, and Tukey tests,

p < 0.05].

Curiously, the number of line-crosses exhibited

by saline-treated rats (M = 3.50) were less than in
Experiment 1 (M = 43.62).

This was most likely due to

handling stress caused by multiple injections.
Rectal Temperatures.

Rectal temperature data were

analyzed using a 3 x 3 within-subjects ANOVA (see Appendix
F).

Rectal temperatures of rats given nor-BNI and U50,488

or clonidine are shown in Figure 6.

Rats given clonidine

had lower rectal temperatures than saline controls [agonist

drug main effect, F(2, 14) = 30.21, p < 0.001, and Tukey

tests, p < 0.05].

When given alone^ neither U50,488 nor

nor-BNI affected rectal temperatures.

nor-BNI did not

alter clonidine-induced reductions in rectal temperatures.
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Figure 5. Mean line-crosses (±SEM) of ll-day-old rats (n =
8) administered nor-BNI (0, 5, or 10 mg/kg) 30 min prior to

behavioral testing and saline, 1750,488 (2.5 mg/kg) or
clonidine (0.25 mg/kg) 15 min prior to behavioral testing.

^Significantly different from similarly treated rats given

saline; '^Significantly different from rats given 1750,488 and
0 mg/kg nor-BNI.

42

37.0

I

36.5
o
o

36.0

CO

2

35.5

ZD

2

T

35.0

Lt

0
Q.

10 mg/kg nor-BNI
5 mg/kg nor-BNI
10 mg/kg nor-BNI

34.5

E
0

1

34.0

15

33.5

"C
0

Q1

33.0

32.5
32.0

Saline

U50,488

Clonidine

Agonist Treatnnent

Figure 6. Mean rectal temperatures (±SEM) of 11-day-old
rats (n = 8) administered nor-BNI (0, 5, or 10 mg/kg) 30
min prior to behavioral testing and saline, U50,488 (2.5
mg/kg), or clonidine (0.25 mg/kg) 15 min prior to
behavioral testing. Rectal temperatures were measured
immediately following the 20 min behavioral testing

session.

^Significantly different from saline-treated rats

collapsed across agonist treatment.
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EXPERIMENT 3

It was expected that nor-BNI would attehuate U50,488
and clonidine-induced USVs.

Therefore, in the third

experiment, the interaction of K-opioid and a2-noradrenergic
systems were further investigated by injecting yohimbine in
combination with clonidine or U50,488.

I predicted that

yohimbine would cause a dose-dependent decrease in the
. nhmber of'NS0,.'488- ■ and clonidine-induced US

.

Method

litters (N = 72) of 11-day-old rats were

injected with yohimbine (0.0, 0.5, or 1.0 mg/kg, ip) and

placed: in their home cage for;15 min .^ ^ ::Rat pups were then;,, ■
ifijected with saline, USO,488 (2,5

;(0;25: mg/kg^ ipjl

ipf;

After an additionai 15 min, USVs and^v ^

locomotor activity were measured in the testing chamber for
20 min (divided into four 5-min time blocks).

Rectal

temperatures were taken immediately after testing.

Rat

pups were then placed in a room separate from theirs dam and
littermates.

To analyze USVs, a 3 X 3 x 4 (antagonist drug x agonist
drug X time) within-subjects repeated measures ANOVA was
used.

Line-crosses and rectal temperatures were analyzed
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using 3 X 3 (antagonist drug x agonist drug) within-subjects
ANOVAs.

Results

Ultrasonic Vocalizations.

USV data were analyzed

using a 3 x 3 x 4 within-subjects repeated measures ANOVA

(see Appendix G).

USVs of rats given yohimbine and U50,488

or clonidine are shown in Figure 7.

Rats treated with

U50,488 or clonidine produced more USVs than saline-treated

rats [agonist drug main effect, F(2, 12) = 49.71, p <

0.001, and Tukey tests, p < 0.05].

Yohimbine (0.5 or 1.0

mg/kg) decreased USV emissions of saline-treated rats on
time blocks 1 and 2 (upper graph) [antagonist drug x agonist
drug X time interaction, F(12, 72) = 2.94, p <0.01, and

Tukey tests, p < 0.05].

Yohimbine also attenuated U50,488

induced USV production in a dose-dependent manner.

Specifically, 0.5 mg/kg yohimbine decreased U50,488-induced
USV production on time blocks 1, 3, and 4 [Tukey tests, p <
0.05]; whereas, 1.0 mg/kg yohimbine decreased U50v488
induced USVs on all time blocks (middle graph) [Tukey

tests, p < 0.05].

Both doses of yohimbine (0.5 or 1.0

mg/kg) deicreased clonidine-induced USV production on all
time blocks (bottom graph) [Tukey tests, p < 0.05].
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Line-crosses,.

Line-cross data', were analyzed using a 3.

X 3 within-subjects ANOVA (see Appendix H).

Line-crosses of

rats given yohimbine and U50,488 or clonidine are shown in
Figure 8.

Rats given U50,48:8, but hot clonidine, had more

line-crosses than.saline-treated rats [Tukey tests, p <
0.05].

interestingly, both doses of yohimbine (0.5 and 1.0

mg/kg) attenuated U,50,488-induced line-crosses [antagonist
drug X agonist drug interaction, F(4, 24) = 9.55, p < 0.001,

and Tukey tests, p < 0.05].

Yohimbine did not affect line-

crosses of saline- or clonidine-treated rats.

The total

number of line-crosses produced by saline-treated rats was

consistent with Experiment 2.
Rectal Temperatures.

Rectal temperature data were

analyzed using a 3 x 3 within-subjects ANOVA (see Appendix
I).

Rectal temperatures of rats given yohimbine and

U50,488 or clonidine are shown in Figure; 9.

Once again,

clonidine-treated rats had lower rectal temperatures than

saline- or U50,488-treated rats [agonist drug main effect,
F(2, 12) = 27.00, p < 0.001, and Tukey tests, p < 0.05].
Overall, yohimbine did not affect the rectal temperatures
of rat pups.
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Figure 7. Mean ultrasonic vocalizations (±SEM) of 11-day
old rats (n = 7) administered yohimbine (0.0, 0.5, or 1.0
mg/kg) 30 min prior to behavioral testing and saline,

U50,488 (2.5 mg/kg) , or clonidine (0.25 mg/kg) 15 min prior

to behavioral testing.

^Significantly different from rats

given 0.0 mg/kg yohimbine (open circles) .
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Figure 8. Mean line-crosses (iSEM) of li-day-old rats (n =
7) administered yohirabine (0.0, 0.5, or l.G mg/kg) 30 min

prior to behavioral testing and saline, U50,488 (2.5 mg/kg)
or clonidine (0.25 mg/kg) 15 min prior to behavioral
testing. ^Significantly different from similarly treated

rats given saline; ^'significantly different from rats
administered U50,488 and 0.0 mg/kg yohimbine.
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Figure 9. Mean rectal temperatures (±SEM) of 11-day-old
rats (n = 7) administered yohimbine (0.0, 0.5, or 1.0

mg/kg) 30 min prior to behavioral testing and saline,
U50,488 (2.5 mg/kg), or clonidine (0.25 mg/kg) 15 min prior
to behavioral testing. Rectal temperatures were measured
immediately following the 20 min behavioral testing

session.

^Significantly different from saline-treated rats

collapsed across agonist treatment.
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DISCUSSION

The purpose of the present study was to assess whether

the K-opioid and the a2-noradrenergic systems interact when
mediating USV production and locomotor activity of

preweanling rats.

Similar to previous studies, saline-

treated rats emitted a moderate number of isolation-induced

USVs that decreased as the testing session progressed

(Blumberg, Efimova, & Alberts, 1992; Kehoe & Harris, 1989).
As predicted, clonidine increased the USV production of 11
day-old rats in a dose-dependent manner (see Blumberg,
Kreber et al., 2000; Hansen, 1993; Hard et al., 1988; Kehoe
& Harris, 1989).

Also, rat pups treated with U50,488

emitted more USVs than saline-treated rats (see Barr et

al., 1994; Garden et al., 1994; Kehoe & BoyIan, 1994;
Nazarian et al.,, 1999).

The interaction of K-opioid and a2-noradrenergic

systems was examined in two ways.

First, by assessing the

effects of the K-opioid antagonist nor-BMI on U50,488- and

clonidine-induced USV production.

Second, by assessing the

effects of the a2-noradrenergic antagonist yohimbine on
U50,488- and clonidine-induced USV production.

In contrast

to my initial prediction, nor-BNI decreased U50,488-, but
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not clonidine-, induced USVs.

Yohimbine, on the other

hand, decreased both U50,488- and clonidine-induced USVs.

Therefore, it appears that the K-opioid and a2-noradrenergic

systems interact when mediating USV production, but in a
more complex manner than originally hypothesized.
The K-opioid agonist affected locomotor activity in a
consistent manner, because rat pups treated with U50,488
had more line-crosses than saline-treated rats (see

Experiments 2 and 3).

In contrast, clonidine's effects on

locomotor activity varied according to experiment.

More

specifically, clonidine reduced the line-crosses of

preweanling rats in Experiment 1; whereas, clonidine did
not significantly affect line-crosses in Experiments 2 and
3.

The inability of clonidine to decrease line-crosses in

the latter two experiments was probably due to a "basement
effect", as the saline controls exhibited minimal line-

crosses (M = 4.32) in Experiments 2 and 3 (i.e., a
clonidine-induced reduction in line-crosses was impossible

to detect).

Both nor-BNI and yohimbine depressed U50,488

induced locomotor activity, while neither antagonist

affected the locomotor activity of saline- or clonidine
treateti rats.
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Rectal temperatures were differentially affeGted. by
the various drugs.

Clonidine consistently reduced rectal

temperatures qf rat pups in all thrqe experiments.

Op the

Other hand, U50,4.88 did not affectlrectal temperatures.

Neither ahtagonist wad able to block the clohidine-induced
reduction in rectal temperatures.

production: Role Of the a2-noradrenergic system. ;

As just mentioned, clonidine enhanced the USV production of
11-day-old rats.

Clonidine-induced USVs can be explained ;

through at least three different mechanisms.

First,

clonidine may stimulate aa-adrenoceptors in brain regions ;
involved with USV production.

More specifically, clonidine

may induce USV production by stimulating a2-adrenoceptors in
brain regions involved with affective behaviors, such as ,
the amygdala, striatum, nucleus accumbens, and
periaqueductal gray (PAG).
Second, clonidine may indirectly enhance USV

production by affecting central pathways mediating
cardiovascular functioning.

It has been previously shown

that clonidine stimulates a2-adrenoceptors in the medulla or
other brain stem nuclei involved in cardiovascular

functioning (Van Zwieten, 1986; 1996).
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This clonidine

induced stimulation may enhance USV production by
decreasing heart rate and blood pressure.

Third, clonidine may increase USV production by

directly stimulating presynaptic a2-adrenoceptors on nerve

terminals synapsing the heart.

Direct stimulation of

presynaptic a2-adrenoceptors inhibits the release of
norepinephrine and decreases heart rate and blood pressure
(Drew,- 1976; Misu, Fujie, & Kubo, 1982).

Altogether, it

appears that clonidine may induce USVs by: 1) producing a
State of emotional distress in the rat pup that results in

USV emissions, 2) modulating circuitry in the brain stem
involved with heart functioning, or 3) directly acting on
peripheral noradrenergic neurons that decrease heart rate
and, thus, increase USVs.

USV production: Role of the K-opioid system.

Similar

to previous studies, U50,488 increased the iJSV production
of 11-day-old rats (Barr et al., 1994; Garden et al., 1994;
Kehoe & Boylan, 1994; Naz;arian et al., 1999).

One

possibility is that U50,488 stimulates USV production by
activating K-opioid receptors in the striatum, nucleus

accumbens, amygdala; or PAG (i.e., brain regions known to
be involved in affective behaviors).
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Alternatively,

U50,488 may activate K-opioid receptors in brain regions
involved in cardiovascular functioning.

For instance,

stimulation of K-opioid receptors in the hippocampus,

hypothalamus, and medulla decreases the heart rate and
blood pressure of adult rats (Feuerstein & Faden, 1982;
Hassen, Feuerstein, & Faden, 1984; Wang & Ingenito, 1994).
The decreased heart rate could, in turn, be responsible for
the increased USV emissions.

It is also possible that activating peripheral K-opioid
receptors may enhance USV emissions of rat pups.

Stimulation of K-opioid receptors, located on noradrenergic
nerve terminals at the heart, decreases heart rate and

blood pressure (Fuder et al., 1986; Ledda et al., 1985;
Starke et al., 1985).

Hence, the decrease in heart rate

and blood pressure may increase USV production.

Therefore,

similar to clonidine, U50,488 may enhance USVs by: 1)

producing a state of emotional distress by acting on brain

regions involved in affective behaviors, 2) modulating
brain circuitry concerned with heart functioning, or 3)

directly inhibiting the release of norepinephrine at the
heart.

Taken together, it is possible that U50,488 and

clonidine may produce USVs through similar mechanisms.
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Role of the K-opioid system on aa-noradrenergic

mediated USV production.

As noted earlier, the purpose of

this study was to assess the interaction between the k-

opioid and the a2-noradrenergic systems.

The present study

showed that nor-BNI attenuated U50,488-induced USV

production of 11-day-old rats in a dose-dependent manner.
On the other hand, nor-BNI (a K-opioid antagonist) did not

reduce the USVs of rats given clonidine (a a2-noradrenergic

agonist).

Thus, results from this particular experiment

suggest that the K-opioid system does not modulate a2
noradrenergic-mediated USV production.
Role of the a2-noradrenergic system on K-opioid
mediated USV production.

Other evidence suggests that the

K-opioid and a2-noradrenergic systems interact when
mediating USV production.

Specifically, it appears that

the a2-noradrenergic system modulates K-opioid-mediated USV
emissions, as yohimbine decreased both U50,488- and
clonidine-induced USV production in a dose-dependent
manner.
rats.

Yohimbine also reduced the USVs of saline-treated
,
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Based on this pattern of results, it appears that the
a2-noradrenergiG system modulates K-opioid-medisted USV

prodUGtion.

Gonversely, manipulation of the K-opioid system

had no effeot on a2-noradrenergiG-mediated USVs.

Therefore,

the K-opioid and az-noradrenergio systems seem to interaot
in a unidireotional manner.

The most parsimdnidus

explanation is that the K-opioid reoeptors modulating USV
produGtion are loeated "up-stream" from the oritioal a2
noradiehergic neurons.

For instance, the K-opioid system

may mediate USV pidduotion'through higher brain oenters
(e.g., the striatum or PAG), while the a2-noradrenergiG
system may mediate USV production through brain stem areas.
Due to this unidireotional arrangement, the a2-noradrenergic

system would be able to alter K-opioid-mediated USV
produGtion, but the reverse would not be true.
The interaotion between K-opioid and a2-noradrenergiG

systems on looomotor aotivity.

In the present study,

Glonidine-treated 11-day-old rats had fewer line-Grosses
than saline oontrols.

This result is somewhat ourious

beoause a number of studies have reported that olonidine

enhanoes looomotor aotivity of rat pups (Kehoe & Harris,
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1989; Nomura & Segawa, 1979; Pappas & Walsh, 1983;

Reinstein & Issacson, 1977; Smythe & Pappas, 1989).

This

inconsistency is most likely due to the method of assessing
locomotor activity.

Studies that operationally define

locomotor activity in terms of line-crosses (a direct
measure of forward locomotion) typically report that

clonidine reduces locomotion (Hansen, 1993; present study);
whereas, studies that operationally define locomotor

activity in terms of general motoric movement (i.e., by
collapsing such measures as forward locomotion, paddling,
circling, and wall climbing) find that clonidine enhances
movement (Kehoe & Harris, 1989; Nomura & Segawa, 1979;

Pappas & Walsh, 1983; Reinstein & Issacson, 1977; Smythe &
Pappas, 1989).

Consequently, it is likely that clonidine

reduces the locomotor activity of preweanling rats, while
increasing general motoric movement.
Stimulation of K-opioid receptors produces a

paradoxical increase in the locomotor activity of rat pups.
That is, K-opioid agonists (e.g., U50,488 and enadoline)
decrease locomotor activity of adult rats, while increasing
the locomotor activity of preweanling rats (Garden et al.,
1994; Crawford et al., 1995; Kehoe & Boylan 1994; McDougall
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et ai./ 1999; McLaughlin et al.y 1995; VonVoigtlander et
al., 1983).

Gonsistent with past studies, US0,488 produced

a nor-BNI reversible enhancement in the locomotor activity

of ll-day-old rats (see also Collins et al., 2000;
McLaughlin et al., 1995).

Ah unexpected finding was that yohimbine reduced
US0,488-induced locomotor activity.

Although not

previously shown, it is possible that a2-noradrenergic and
K-bpioid systems interact to decrease USO,488-induced

locbmotor activity.

This suggestion, however, requires

further investigation.

An alternative possibility is that

yohimbine may decrease USO,488-induced locomotor activity

by altering dopamine system functioning.
possibility is three-fold.

Evidence for this

First, yohimbine antagonizes,

dopamine bs-like receptors (Heal et al., 1987; Scatton,
Zivkovic, Sc Dedek, 1980).

Second, yohimbine attenuates

amphetamine- and apomorphine-induced locomotor activity of
adult rats (Heal et al., 1987 ,* Luttinger & Durivage, 1986).

Importantly, the doses of yohimbine (1 and 3 mg/kg) found
to attenuate amphetamine- and apomorphine-induced locomotor

activity were similar to those used in the present study.
Third, dopamine antagonists attenuate USO,488-induced line
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crosses in rat pups (Duke et al., 1997; Mazarian. et al.,
1999).

It should be noted that:yohirabine does not reduce

USy production by blocking D2-like receptors because

dopamine antagonists have no effect on USV production of

rat pups (Dastur, McGregor, & Brown, 1999; Nazarian et al.,
1999).

The, role of .K-opioid and a.2-noradrenergic systems on
rectal temperatures

Consistent with past studies,

clonidine reduced rectal temperatures of ll-day-old rats
(Hard et al., 1988).

On the other hand, U50,488 did not

reduce rectal temperatures. . This may be due to the low

■.

dose (2.5 mg/kg) of U50,488 used in this study, because
higher doses of U50,488 reduce rectal and axillary

temperatures of rat pups (Garden et al., 1993; Nazarian et
al., 1999).

Interestingly, neither nor-BNI nor yohimbine

had any effect on the clonidine-induced reduction of rectal

temperatures.

When considered together, these findings

suggest that U50,488- and clonidine-induced USV production

is independent of drug-induced changes in body temperature.
Conclusion.

Overall, the results of the present study

demonstrate that the K-opioid and a2-noradrenergic systems

interact when mediating USV production.
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This study does

not conclusively resolve whether USV production is a
central or peripheral effect, or whether USVs are the
result of distress or a cardiovascular mechanism.

By combining both current and previous findings, it is
possible to suggest a number of mechanisms that may be

responsible for USV production.

Although speculative, USV

production may be a distress response mediated by brain
regions involved in both affective and cardiovascular
functioning.

Specifically, in adult rats, distress can be

induced by various procedures (e.g., restraint, shock, and
tail-pinch), all of which increase norepinephrine leyels i^^
the amygdala, basal ganglia, hippocampus, hypothalamus,

pens, and medulla (Quirarte, Galvez, Roozendaal, & McGaugh,:
1998; M. Tanaka et al., 1983; T. Tanaka et al., 1991).

These brain regions are, involved,in both affectiye:^^.:^ , 
(amygdala and basal ganglia) and cardiovascular

(hippocampus, hypothalamus, pons, and medulla) functioning.
It is possible that young rats may show similar increases
in distress-induced norepinephrine levels.

If this is

true, then it may explain the underlying mechanisms

responsible for USV production.

That is, distress may

increase norepinephrine levels in brain regions involved in
affective and cardiovascular functioning.
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The increase in

norepinephrine levels may deGrease blood pressure and heart
rate and provoke USV emissions.

It is clear that USVs can be produced by distressing
the rat pup or by independently altering the cardiovascular
system.

However, one should consider that both mechanisms

may be jointly involved in producing USVs.

That is, when

an organism is crying, yelling, sneezing, or laughing,
physiological mechanisms are involved that cause air to be
exhaled from the larynx.

Nonetheless, affect is inherently

involved because voluntary actions (e.g., laughing or
crying), similar to involuntary actions (e.g., sneezing),

also activate the same physiological mechanisms (i.e., air
exhaled from the larynx).

When considering the adult and

pup distress literature together, it appears that
isolation-induced USV production is an emotionally-mediated
behavior that requires the participation of brain regions

involved in both affective and cardiovascular functioning.
Synopsis.

The present study was a first step in

trying to better understand the underlying mechanisms
responsible for USV production.

The function of USVs has

been of great dispute in recent years (Blumberg, Sokoloff
et al., 2000; Hofer & Shair, 1993). , According to the
distress model, USVs are interpreted to be an emotionally

,
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mediated behavior produced by rat pups in order to gain the
attention of the dam for nurturance, protection, and

thermoregulation (Bell, 1979; Smotherman et al., 1974).
This model interprets USVs as a distress call emitted by

rat pups, which can be modulated by various pharmacological

agents known to alter distress and anxiety.

For instance,

drugs that reduce USV production are considered to be
rewarding (e.g., cocaine and morphine) or anxiety reducing

(e.g., diazepam), while drugs that enhance USVs (e.g., ,
U50,488) are considered to be aversive or anxiogenic
(Garden et al., 1990; 1994; Insel et al., 1986; Kehoe &

BoyIan, 1992).

Therefore, according to the distress model,

USVs are emotionally-mediated voluntary behaviors that are
produced by rat pups when distressed.
In direct opposition, the cardiovascular model

suggests that USVs are simply by-products of abdominal
compression reactions (ACR).

It is believed that rat pups

produce USVs in order to maintain their normal heart rate,

blood pressure, and body temperature when separated from
the dam (Blumberg et al., 1999).

The cardiovascular model

postulates that drugs that enhance or reduce USV production
either directly or indirectly modulate cardiovascular
functioning through either central or peripheral mechanisms
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(Blumberg, Kreber et al., 2000).

Thus, drugs that cause a

decrease in heart rate and blood pressure enhance USV

production.

On the other hand, drugs that increase heart

rate and blood pressure reduce USV production.

Taken

together, proponents of the cardiovascular model discount
the distress model and argue that USVs are a physiological
response with no affective cause.
In the present study, the K-opioid agonist U50,488, and
the a2-noradrenergic agonist clonidine independently
enhanced USV production.

.

I attempted to attenuate U50,488

and clonidine-induced USV production by using the K-opioid

antagonist nor-BNI and the a2-noradrenergic antagonist
yohimbine.

By doing so, I was interested in learning

whether the K-opioid and the a2-noradrenergic systems
interact when mediating USV production.

Results showed

that the K-opioid and the a2-noradrenergic systems interact
in a very specific manner.

The findings demonstrate that

U50,488-induced USV production was attenuated by nor-BNI

and yohimbine, while clonidine-induced USV production was
reduced by yohimbine but not nor-BNI.

This pattern of

results suggests that the a2-noradrenergic system modulates
K-opioid-mediated USV production, but that the K-opioid
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system does not modulate aa-noradrenergic-mediated USV
production.

It is possible that USVs are emotionally-mediated
calls that require the joint activation of both affective
and cardiovascular centers in the brain.

This conclusion

is supported by findings showing that both distress and
anxiety increase norepinephrine levels in brain regions
involved in affective and cardiovascular functioning.

In

turn, USV emissions may ultimately be produced by changes
in cardiovascular functioning and the onset of ACRs.
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Appendix A

ANOVA 'Table for USV Data of Experiment 1
Source

Total

Qi

:

16352588.98

Agonist (Agon)
> ErrorAgon(

ch

SS

3388146.98/ r
; 8792978.35 /
4171463.65 . '

df " :
39

^:

MS. ■

2831246.44.

7
4

2198244,60

28

148980.84

484021.00

14.76

<0,001

Appendix B
ANOVA Table for Line-Cross Data of Experiment 1
Source

Total

Siubject
Agonist (Agon)
ErrorAgon

<j\
CTi

SS

df

MS

27553.10

39

3483.16

3209.90

7

458.56

10057.60

4

2514.40

14285.60

28

510.20

4.93

< 0.01

Appendix C

>

ANOVA Table for Rectal Temperature Data of Experiment 1
Source

Total

Subject
Agonist (Agon)
ErrorAgon

CTi
<1

SS

df

MS

31.36

39

5.20

6.71

7

0.96

15.68

4

3.92

8.97

28

0.32

F

12.24

< 0.01

Appendix D
ANOVA Table for USV Data of Experiment 2
Source

Total

Subject
Antagonist (Antag)
Agonist (Agon)

CX)

df

MS

17462694.01

287

5811937.04

266870.72

7

38124.39

2884143.56

2

1442071.80

43.91

< 0.001

5928019.77

2

2965009.90

55.91

< 0.001

8275.03

3

2758.34

1.39

< 0.275

Antag x Agon

4677555.42

4

1169388.90

20.87

<

0.001

Antag x Time
Agon X Time

62832.24

6

10472.04

2.14

<

0.068

143260.45

6

23876.74

6.20

< 0.001

54524.28

12

4543.69

1.48

<

459798.55

14

32842.75

742234.84

14

53016.77

41781.81

21

1989.61

ErrOrAntagxAgon

1569172.64

28

56040.81

ErrorAntagxTime

205296.09

42

4888.00

ErrOrAgonxTime

161788.05

42

3852.10

ErrOrAhtagxAgonxTime

257140.56

84

3061.20

Time

cr\

SS

Antag x Agon x Time
Errorantag,
ErrorAgon .
ErrorTime

0.146

E

ANOVA Table for Line-Gross Data of Experiment 2
SS

Source

Total

Subject
Antagonist (Antag)
Agonist (Agon)
Antag x Agon

ErrorAiitag^ ,
■
Ch
vo

\

.

df :

MS

124137.62

71

38423.85

v !1905:78
1672':7;:86;

, 7

272.25

40016.72

:32400.66
: 983E.81

72^

8363.93

2

20008.36

.14

: 702^.63

8100.16

ErrorAgoH^. ; , .r

4092:95

392.35

ErrOrAntagxAgon

19156.84

684.17

11.90

< 0.001

68.44 : < 0.001
11.84

<0.001:

Appendix F

AMOVA Table for Rectal Temperature Data of Experiment 2
Source

df

SS

Total

94.84'

26.16

Antagonist (Antag)
Agonist (Agon)
Antag x Agon

,

; , : Errorjtotag /
'ErrorAgon ^

ErrOrAntagxAgon
<1
o

MS

71

26.42

:7

3.74

0 il5

2

0,08

0.19

0.829

41.59

yi

20.79

30.21

0:001

0.95

0.450

1.40

4

0.35

5.57

.14

0.40

9.64

14

0.69

10.33

28

0.37

Appendix G
ANOVA Table for USV Data of Experiment 3
SS

df

MS

10233072.89

251

3580205.23

252476.22

6

42079.37

1921607.72

2

960803.86

40.11

<

0.001

4505085.77

2

2252542.90

49.71

<

0.001

10350.23

3

3450.08

0.85

<

0.485

Antag x Agon

640540.49

4

160135.1,2

2.55

<

0.066

Antag x Time
Agon X Time

16963.71

6

2827.28

1.17

<

0.346

49387.28

6

8231.21

3.18

<

0.013

79476.46

12

6623.04

2.94

<

0.002

Source

Total
ect

Antagonist (Antag)
Agonist (Agon)
Time

<!

Antag x Agon x Time
ErrorAntag
ErrorAgon

287476.11

12

23956.34

543728.56

12

45310.71

73045.46

18

4058.08

ErrOrAntagxAgon

1509995.17

24

62916.47

ErrorAntagxTime

87304.68

36

2425.13

ErrorAgonxTime

93251.28

36

2590.31

162383.65

72

2255.33

ErrorTime

ErrorAntagxAgonxTime

, .

Appendix H

ANOVA Table for Line-Cross Data of Experiment 3
SS

Source

Total

Subject
Antagonist (Antag)
Agonist (Agon)
Antag x Agon

<1
to

df

MS

331940.42

62

118265.33

21131.97

6

3521.99

22781.56

2

11390.78

9.20

<

0.004

178406.89

2

89203.44

29.21

<

0.001

9.55

35692.25

4

8923.06

ErrorAntag
ErrorAgon

14854.89

12

1237.91

36642.89

12

3053.57

ErrOrAntagxAgon

22429.97

24

934.58

< 0.001

Appendix I
ANOVA Table for

Source

Subject
Antagonist (Antag)
Agonist (Agon)
Antag x Agon

ErrorAntag
ErrorAgon
ErrOrAntagxAgon

Data of

df

SS

Total

<1
U)

Rectal Temperature

Experiment 3
MS

F

P

67.38

62

13.66

19.26

6

3.21

0.28

2

0,14

0.18

15.71

2

7.85

27.00

< 0.001

2.85

4

0.71

1.04

< 0.406

9.40

12

0.78

3.49

12

0.29

16.39

24

0.68

<

0.841
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